x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DCL-001066
| Product Information | |
|---|---|
| Parental | HeLa |
| Organism | Human |
| Tissue | Cervix |
| Target Name | SCD |
| Cell Type | Epithelial cells |
| Gender | Female |
| Product Description | Knockout achieved by using CRISPR/Cas9, 4 bp deletion in exon3 and Insertion of the selection cassette in exon3. |
| UniProt No. | O00767 |
| Gene ID | 6319 |
| Gene Description | Terminal component of the liver microsomal stearyl-CoA desaturase system, that utilizes O(2) and electrons from reduced cytochrome b5 to catalyze the insertion of a double bond into a spectrum of fatty acyl-CoA substrates including palmitoyl-CoA and stearoyl-CoA. |
| Format | Frozen |
| Growth Properties | Adherent |
| Shipping & Storage | |
|---|---|
| Shipping | Cryopreserved on dry ice. |
| Storage Instructions | Store in liquid nitrogen. |
| Storage Buffer/Media | 8.7% Dimethylsulfoxide, 2% Cellulose, methyl ether |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
